All News – Featured Article 1

Risk of secondary cancer after CAR-T cell therapy is low, according to major Stanford Medicine study

Researchers analyzed outcomes for 724 people treated with CAR-T cell therapy at Stanford Health Care between 2016 and 2024. Among…